Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis

Frontiers in Oncology

Lu Zhao¹  Peng Zou¹  Rong Zhang²  Wenwen Xia²  Qiwen Zhu³  Yan Zhang⁴ 

[1] Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenyang Medical College, Shenyang, China;Department of Biopharmaceutics, School of Life Science and Bio-Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China;Key Laboratory of Behavioral and Cognitive Neuroscience of Liaoning Province, Shenyang Medical College, Shenyang, China;School of Traditional Chinese Medical, Shenyang Medical College, Shenyang, China;

关键词: ocular melanoma;    immune checkpoint blockade;    PD-1;    PD-L1;    CTLA-4;    meta-analysis;   

DOI  :  10.3389/fonc.2021.781162

来源: DOAJ

【 摘 要 】

AimThis meta-analysis aimed to compare the efficacy and safety of immune checkpoint blockade for the treatment of ocular melanoma.MethodsWe searched the PubMed, EMBASE, and Cochrane Library databases up to July 2021. Effect sizes (ESs) and corresponding 95% confidence intervals (CIs) were used to compare the outcomes. Efficacy outcomes included complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), overall survival (OS), progression free survival (PFS). Safety outcomes included adverse events (AEs) and serious adverse event (SAEs).ResultsA total of 16 eligible articles with 848 ocular melanoma patients were included. ICB treatment significantly improved CR (ES=0.02, 95%CI: 0.00-0.03, P=0.023), PR (ES=0.07, 95%CI: 0.05-0.09, P=0.000), SD (ES=0.31, 95%CI: 0.17-0.46, P=0.000), PD (ES=0.69, 95%CI: 0.61-0.77, P=0.000), ORR (ES=0.10, 95%CI: 0.04-0.15, P=0.000), OS (ES=9.68, 95%CI: 7.28-12.07, P=0.000) and PFS (ES=2.88, 95%CI: 2.69-3.07, P=0.000) in patients with ocular melanoma. Moreover, ICB therapies were associated with reduced AEs (ES=0.48, 95%CI: 0.30-0.67, P=0.000) and SAEs (ES=0.31, 95%CI: 0.18-0.45, P=0.000).ConclusionsICB therapy showed good efficacy and safety in treating patients with ocular melanoma.

【 授权许可】

Unknown